ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 463

Deficiency of Transmembrane Protein VISTA (V-domain Immunoglobulin Suppressor of T-cell Activation) Ameliorates Murine Collagen-II Antibody-Induced Arthritis

Roy Fava1,2, Sabrina Ceeraz3, Susan Eszterhas4, Petra Sergent3, Christopher Burns5 and Mathew Vincenti6,7, 1Research, Department of Veterans Affairs, White River Junction, VT, 2Department of Medicinee, Geisel School of Medicine at Dartmouth, Lebanon, NH, 3Microbiology/Immunology, Geisel School of Medicine at Dartmouth, Lebanon, NH, 4Research, Department of Veterans Affairs, white River Junction, VT, 5Section of Rheumatology, Geisel School of Medicine at Dartmouth, Lebanon, NH, 6Department of Veterans Affairs, White River Junction, VT, 7Department of Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: complement, immate immune system, inflammatory arthritis, mouse model and therapeutic targeting

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Animal Models - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The transmembrane protein VISTA, is a member of the B7/CD28 family of immune modulator proteins and can function as a negative immune checkpoint regulator through a currently undefined molecular mechanism(s). VISTA is expressed on myeloid cells and activated T-lymphocytes. Interestingly, qPCR analyses showed VISTA mRNA (human ortholog C10orf54) is expressed abundantly in human rheumatoid synovial tissue. The importance of VISTA expression on myeloid cells was investigated in the collagen-II antibody induced arthritis (CAIA) model.

Methods: Joint targeted inflammation was initiated in the CAIA model by passive-immunization of mice with anti-type-II collagen monoclonal antibodies (5-Clone Cocktail, Chondrex, Seattle) and intraperitoneal injection of LPS, 3 days afterwards. The CAIA model does not require lymphocytes for induction of transient, immune-complex driven joint inflammation (duration 14-15 days), but does require complement activation, neutrophils and monocytes. The arthritic response was evaluated for (1) DBA/1J mice treated with anti-VISTA antibody MH5A (Biolegend) versus hamster IgG as control, and also for (2) VISTA-deficient mice versus wild type, C57/B6 mice. 

Results: A sustained attenuation of paw swelling compared to controls was observed from approximately 6-13 days after initiation, for mice treated with anti-VISTA monoclonal antibody MH5A, and for VISTA-deficient mice. Histologic analysis of all major joints involved (knees, ankles, paws) indicated overall reduced joint inflammation/damage in VISTA deficient mice compared to controls. Since C5a generation is crucial to CAIA development, levels of C5a in plasma of wild type and VISTA-deficient mice were determined by ELISA 5 days after passive immunization and found to be equivalent. However, FACS analyses of phagocytic cells isolated from bone marrow as well as in peripheral blood of both arthritic and non-arthritic VISTA-deficient mice consistently displayed reduced C5a receptor expression on neutrophils and on bone marrow derived macrophages. Consistent with these findings, acute C5a receptor responses (ERK, AKT phosphorylation) and chemotaxis to C5a were also diminished in macrophages cultured from VISTA deficient mice.

Conclusion: These findings implicate VISTA in arthritic pathology for the first time, possibly due to a role in recruitment of phagocytes to joints. Antibodies reactive with VISTA may be useful therapeutic agents for autoimmune arthritis where immune-complexes drive joint damage.


Disclosure: R. Fava, None; S. Ceeraz, None; S. Eszterhas, None; P. Sergent, None; C. Burns, None; M. Vincenti, None.

To cite this abstract in AMA style:

Fava R, Ceeraz S, Eszterhas S, Sergent P, Burns C, Vincenti M. Deficiency of Transmembrane Protein VISTA (V-domain Immunoglobulin Suppressor of T-cell Activation) Ameliorates Murine Collagen-II Antibody-Induced Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/deficiency-of-transmembrane-protein-vista-v-domain-immunoglobulin-suppressor-of-t-cell-activation-ameliorates-murine-collagen-ii-antibody-induced-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/deficiency-of-transmembrane-protein-vista-v-domain-immunoglobulin-suppressor-of-t-cell-activation-ameliorates-murine-collagen-ii-antibody-induced-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology